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Abstract
Background: Testing for Borrelia-specific IgM and IgG-antibodies are often performed on a variety
of poorly defined symptoms, and isolated IgM results are a frequent finding, which results in
diagnostic uncertainty and further testing. We wanted to test the hypothesis that Borrelia-specific
assays using recombinant antigens perform differently from assays based on purified flagella antigen.
Methods: We compared the use of recombinant antigens (LIAISON® DiaSorin, Saluggia, Italy) and
purified flagella antigen (IDEIA™ Borrelia, DakoCytomation, Glostrup, Denmark) in the assay for
Borrelia-specific IgM and IgG-antibodies. The assays were tested on an unselected population of
serum samples submitted from general practice. A total of 357 consecutive samples for analysis of
Borrelia IgM and IgG antibodies. Furthermore, we analysed 540 samples for Borrelia-specific IgM or
IgG antibodies first by the IDEIA™ and, if they were positive, the samples were further analysed
using the LIAISON® assay. To verify the correctness of the patient's serological status, discrepant
samples were analysed by line blots (EcoLine, Virotech).
Results: In the consecutive series of 357 samples, the IgM assays detected 308 negative and 3
positive samples with concordant results. Compared with the line blot, the IDEIA™ system
produced 21 false-positive IgM results, whereas the LIAISON® system produced only one false-
positive IgM result. The IgG assays showed 1 positive and 328 negative concordant results. The
LIAISON® system produced 9 true IgG-positive samples that were not detected by the IDEIA™
system, but the former produced 4 positive IgG results that were negative by line blot.
Conclusion: Diagnostic assays based on flagella antigen seem to show more false-positive IgM and
false-negative IgG results than assays based on recombinant antigens. The latter may reduce the
number of presumably false-positive IgM results and identify more IgG-positive subjects, but this
system also produces more false-positive IgG results.
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Background
Infection with Borrelia spp. is the most common vector
borne infection in Europe with an estimated more than
60,000 symptomatic cases annually and a reported inci-
dence from Germany of about 1 per 1,000 population [1].
Infection may result in a variety on clinical symptoms,
including neuroborreliosis with cranial nerve paresis and
radicular pain. Borrelia infections in humans are caused by
B. afzelli, B. garinii and B. burgdorferi sensu stricto. A study
from Germany found that 65% of patients were infected
with B. garinii, 24% with B. afzelii and 11% with B. burg-
dorferi  sensu stricto [2]. Clinical borrelia infection is
divided in three stages, 1) erythema migrans; 2) multiple
erythema migrans, lymphadenosis benigna cutis, neu-
roborreliosis and myocarditis; and 3) arthritis, acroder-
matitis chronica athrophicans and chronic
neuroborreliosis [3].
The diagnosis of neuroborreliosis is difficult. It relies pri-
marily on clinical signs, demonstration of intrathecal anti-
body synthesis and pleocytosis in the spinal fluid [4].
Antibody based assays suffers from lack of standardiza-
tion [5], and borrelia infection is therefore overdiagnosed
based on vague criteria and equivocal serological results
especially IgM positivity without specific IgG-antibodies
[6]. Nucleic acid based molecular diagnosis has an even
lower sensitive [7].
Borrelia spp. is believed to express different antigens in dif-
ferent hosts [8], gene expression is reduced as the Borrelia
adapt to the host [9,10] and consequently serological
diagnosis is difficult and unpredictable in the early stages
of the infection. This partly explains why common con-
sensus on diagnostic criteria is lacking [11]. The flagella
contain the immunodominant 41 kDa, flagellin antigen,
and several outer surface proteins, Osp's. The use of an
enzyme-immunoassay followed by a Western blot or dot
blot assay has not improved diagnostic accuracy [12].
However, Western blotting with a mixture of B. burgdorferi
sensu stricto and B. afzelii antigens have been found to
improve diagnosis in up to 70% of sera with borderline
results [13], but Western blot or immunoblots using
recombinant antigens can not be regarded as a golden ref-
erence standard [14]. Antibody assays have not been use-
ful in the diagnosis of erythema migrans. Patients with
systemic Borrelia infections show IgG-antibodies after up
to eight weeks after infection [15]. Persistent IgM-antibod-
ies with without development of Borrelia-specific IgG-
antibodies is usually regarded as false-positive reactions
[15].
The two diagnostic assays have previously been evaluated
on patients with well defined clinical borrelia infection in
different stages. In patients with erythema migrans, the
flagella assay were found to have a sensitivity of 44.8% in
the IgM assay and 35.5% in the IgG assay [14], while the
recombinant antigen showed a sensitivity of 46.9% in the
IgM assay and 66.3% in the IgG assay [16].
In patients with neuroborreliosis the flagella assay dis-
played a sensitivity of 67.9% for the IgM assay an 76.8%
for the IgG assay [15], whereas the recombinant antigen
assay was found to have a sensitivity of 36.8% for the IgM
assay an 90.8% for the IgG assay [16].
The aim of the present study was to evaluate chemilumi-
nescence immuno assays based on recombinant antigens
(LIAISON®, DiaSorin, Salugia, Italy) and assays based on
purified flagella antigen (IDEIA™, Dako Cytomation,
Glostrup, Denmark). This comparison was performed on
a population based panel of samples submitted from gen-
eral practice for analysis for Borrelia IgM- and IgG-anti-
bodies. In order to compare the two assays, samples with
discordant outcome were analysed by a Lineblot (Eco-
Line, Virotech) to more correctly ascertain the serological
status of the patient.
Methods
Samples
Eight hundred and ninety-seven serum samples submit-
ted primarily from general practitioners for analysis of
Borrelia-specific IgM and IgG antibodies were included.
We included 357 consecutive samples which were all
tested by the recombinant antigen chemiluminescence
immuno assay (LIAISON®) and the purified flagella anti-
gen assay (IDEIA™ Borrelia) independent of the results
from the other test systems, and samples were recruited no
matter whether submitted from general practice or from
hospitalized patients. Samples with equivocal results were
included. Patients have not been selected based on sex or
age. All patients were permanent residents in Denmark.
Patients occurred only once in each dataset. These consec-
utive samples were collected from December 2003 to May
2004 and the selected samples from the end of January to
the end of April 2004. The five hundred and forty samples
collected from January to December 2003 were tested first
by purified flagella antigen test (IDEIA™ Borrelia, DakoCy-
tomation, Glostrup, Denmark) for Borrelia-specific IgM
and IgG antibodies and samples with a positive IgM or
IgG result from this analysis were further analysed in the
recombinant antigen test (LIAISON®, DiaSorin, Saluggia,
Italy). Samples showing discrepancy in either IgM or IgG
results from these tests were analysed by line blot (Eco-
Line, Virotech).
All samples were anonymised before entered into the
study. Studies on anonymised samples do not require
approval by a scientific ethical committee according to
Danish law.BMC Clinical Pathology 2008, 8:4 http://www.biomedcentral.com/1472-6890/8/4
Page 3 of 8
(page number not for citation purposes)
Assays
Purified flagella antigen enzymeimmuno assay (IDEIA™ Borrelia 
burgdorferi, DakoCytomation, Glostrup, Denmark)
The samples were tested by the standard assay applied by
the Department of Clinical Microbiology, using the Borre-
lia burgdorferi purified flagella antigen, IgM µ-capture
assay and IgG sandwich ELISA assay from DakoCytoma-
tion according to the instructions provided by the manu-
facturer as described by Hansen (1994) [14]. The
diagnostic sensitivity for the assay is in patients with
eythema migrans 44.8% for the IgM assay and 35.5% for
the IgG assay [14], in patients with neuroborreliosis
67.9% for the IgM assay and 76.8% for the IgG assay [14]
and in patients with acrodermatitis 12% for the IgM assay
and 100% for the IgG assay [14]. We have not been able
to find data on specificity for this assay.
A positive test was defined according to the manufac-
turer's recommendations. As proposed by DAKO Cytoma-
tion, readings +/- 10% of the cut off value for IgM and +/
- 20% of the cut off value for IgG were considered as
equivocal. Values higher than these were considered as
positive.
Recombinant antigen enzymeimmuno assay (LIAISON®, DiaSorin, 
Saluggia, Italy)
The samples were tested by recombinant Borrelia IgM and
IgG assays. A positive test is defined according to the man-
ufacturer's recommendation. Samples with Borrelia burg-
dorferi IgG concentrations equal or above 15 AU/ml were
graded positive. Samples with Borrelia burgdorferi IgM con-
centrations equal or above an index value of 1.1 were
graded positive. The assay is an indirect chemilumines-
cence immunoassay based on recombinant antigens pro-
duced in E. coli. LIAISON® Borrelia  IgM utilize a solid
phase coated with recombinant Osp C, Borrelia afzelii,
strain pKo. OpsC is immunodominant for the IgM
response. LIAISON® Borrelia IgG make use of recombinant
VlsE, B. garinii, strain pBi, an outer surface lipoprotein
[17]. In patients with erythema migrans the IgM assay has
a sensitivity of 46.9% and the IgG assay 66.3% [15], in
patients with neuroborreliosis 36.8% for the IgM assay an
90.8% for the IgG assay [15]. The diagnostic specificity of
a negative IgM test is 99% and of a negative IgG test
98%[15]. The code number of the Borrelia IgM version
used in the study is 310890 and the code for Borrelia IgG
is 310880.
Borrelia EcoLine®, Borrelia burgdorferi, (Virotech, Rüselheim, 
Germany)
The test principle is a series of dot blots with recombinant
and purified native Borrelia antigens blotted onto a nitro-
cellulose strip. The IgM-test includes OspC, VlsE, BmpA
and an Epstein-Barr virus antigen. The IgG-test includes
recombinant VlsE, BmpA, p83, BBA36, BBO323, Crasp3
and pG, but it is not stated which Borrelia subspecies the
different antigens comes from. The tests were interpreted
as recommended by the manufacturer.
Statistics
The two assays were compared using Bowker's test for
symmetry using SAS version 9.1 [18]. The test makes no
assumption on true positive or negative results of the two
tests but only test symmetry in the two by two tables.
Results
Consecutive samples
The concordance between the recombinant antigen assay
(LIAISON®) and the purified flagella antigen assay
(IDEIA™) for Borrelia-specific IgM- and IgG-antibodies
from the series of consecutive samples is summarized in
table 1 and 2. Out of the 357 consecutive samples col-
lected from December 2003 to May 2004, 308 were nega-
tive and 3 were positive in both of the IgM assays (Table
1. Bowker's test statistic 25.7; p < 0.0001). In the IgG-
assays, one tested positive for Borrelia-specific IgG-anti-
bodies in both the recombinant antigen test (LIAISON®)
and the purified flagella antigen test (IDEIA™) and 328
tested negative by both assays (Table 2. Bowker's test sta-
tistic 25.3; p < 0.0001).
Thirty-three of the consecutive samples were IgM positive
in the purified flagella antigen test (IDEIA™) assay but
negative by the recombinant antigen IgM test (LIAISON®).
These samples were further tested by the Borrelia EcoLine®
line blot and 63.6% (21/33) were negative, 12.1% (4/33)
Table 1: Borrelia specific IgM comparing recombinant antigen assay (LIAISON®) and purified flagella assay (IDEIA™). Consecutive, 
unselected samples.
Purified flagella Borrelia IgM (IDEIA™)
POS EQV NEG
Recombinant antigen Borrelia IgM (Liaison®)P O S 3 1 6 1 0
EQV 0 0 0 0
NEG 33 6 308 347
36 7 314 357
Bowker's test statistic 25.7; p < 0.0001BMC Clinical Pathology 2008, 8:4 http://www.biomedcentral.com/1472-6890/8/4
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were Epstein Barr Virus positive and potentially cross reac-
tive, 9.1% (3/33) were equivocal and 5/33 (15.2%) were
positive (Table 3). Six samples were IgM negative in the
purified flagella antigen test (IDEIA™) assay but positive
by the recombinant antigen IgM test (LIAISON®). These
samples were further tested by line blot and 83.3% (5/6)
showed positive results and 16.7% (1/6) were negative.
Both tests missed line blot-positive samples found by the
other test, and the recombinant antigen IgM test (LIAI-
SON®) came out with one probable false positive result
whereas the purified flagella antigen IgM test (IDEA®) gen-
erated thirty probable false positive IgM results compared
to the line blot.
Seventeen samples were IgG negative in the purified flag-
ella antigen test (IDEIA™) assay but IgG positive in the
recombinant antigen test (LIAISON®), and these where
further tested by line blot. Of the 17 samples 15 were
available for line blot and 26.7% (4/15) were negative,
13.3% (2/15) were equivocal and 60.0% (9/15) were pos-
itive according to the definition by the manufacturer
(Table 4). The recombinant antigen test (LIAISON®) thus
seems to have a higher sensitivity for detection of Borrelia-
specific IgG-antibodies.
Samples selected for IgM or IgG positivity by the purified 
flagella antigen assay (IDEIA™ Borrelia burgdorferi 
sensu stricto)
Five hundred and forty samples obtained from the end of
January to the end of April 2004 were tested with the puri-
fied flagella antigen assay (IDEIA™) and 80 of these sam-
ples were found positive in either IgM, IgG or both and
were then further tested by the recombinant antigen assay
(LIAISON®). Fifty-three samples were IgM positive in the
purified flagella antigen IgM assay (IDEIA™), but only
5.6% (3) were positive in the recombinant antigen IgM
assay (LIAISON®) and 90.5% (48) were negative by
recombinant antigen IgM assay (Table 5). In the IgG
assays no sample was negative by the recombinant anti-
gen IgG assay (LIAISON®) assay when positive in the puri-
fied flagella antigen IgG assay (IDEIA™). Sixty-one
samples were negative in the purified flagella antigen IgG
assay (IDEIA™), but were selected in this series because of
IgM positivity in the initial purified flagella antigen IgM
assay. Of these, 21.3% (13) were positive in the recom-
binant antigen IgG assay (Table 6). Of the 48 IgM positive
samples 43 were available for line blot and 55.8% (24/43)
were negative, 9.3% (4/43) were Epstein Barr Virus posi-
tive and potentially cross reactive, 9.3% (4/43) equivocal
and 25.6% (11/43) were positive according to the defini-
tion by the manufacturer (Table 7). One sample was IgM
negative in the purified flagella antigen assay but positive
by the recombinant antigen IgM test and these samples
showed a probable positive result in the line blot.
Of the 13 recombinant antigen IgG positive, purified flag-
ella antigen IgG Negative samples, 12 were available for
line blot and 75% (9/12) were positive, 25% (3/12)
equivocal and none were negative (Table 8).
Discussion
The present study was performed on unselected samples
submitted primarily from general practice and thus
reflects the results of everyday practice in a diagnostic lab-
Table 2: Borrelia specific IgG comparing recombinant antigen assay (LIAISON®) and purified flagella assay (IDEIA™). Consecutive, 
unselected samples.
Purified flagella Borrelia IgG (IDEIA™)
POS EQV NEG
Recombinant antigen Borrelia IgG (LIAISON®)P O S 1 2 1 7 2 0
EQV 1 0 8 9
NEG 0 0 328 328
22 3 5 3 3 5 7
Bowker's test statistic 25.3; p < 0.0001
Table 3: Borrelia specific IgM line blots. Consecutive, unselected samples.
Line blot
Total Positive Equivocal Negative EBV
Recombinant antigen positive, Purified flagella antigen negative 6 5 - 1 -
Recombinant antigen positive, Purified flagella antigen equivocal 1 1 - - -
Recombinant antigen negative, Purified flagella antigen positive 33 5 3 21 4
Recombinant antigen negative, Purified flagella antigen equivocal 6 1 - 5 -BMC Clinical Pathology 2008, 8:4 http://www.biomedcentral.com/1472-6890/8/4
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Table 4: Borrelia specific IgG line blots. Consecutive, unselected samples.
Line blot
Total Positive Equivocal Negative EBV
Recombinant antigen positive, Purified flagella antigen negative 15 out of 17 9 2 4 -
Recombinant antigen positive, Purified flagella antigen equivocal 2 2 - - -
Recombinant antigen equivocal Purified flagella antigen positive 1 1 - - -
Recombinant antigen equivocal Purified flagella antigen negative 6 out of 8 1 2 2 1
Table 5: Borrelia specific IgM comparing recombinant antigen assay (LIAISON®) and purified flagella assay (IDEIA™). Selected 
samples.
Purified flagella antigen Borrelia IgM (IDEIA™)
POS EQV NEG
Recombinant antigen Borrelia IgM (LIAISON®)P O S3 0 1 4
EQV 2 0 0 2
NEG 48 16 10 74
53 16 11 80*
*460 samples negative in the purified flagella IgM test (IDEIA™) were not tested in the recombinant antigen IgM assay (LIAISON®).
Table 6: Borrelia specific IgG comparing recombinant antigen assay (LIAISON®) and purified flagella assay (IDEIA™). Selected 
samples.
Purified flagella antigen Borrelia IgG (IDEIA™)
POS EQV NEG
Recombinant antigen Borrelia IgG (LIAISON®)P O S 1 5 3 1 33 1
EQV 1 0 4 5
NEG 0 0 44 44
16 3 61 80*
*460 samples negative in the purified flagella antigen test (IDEIA™) were not tested in the recombinant antigen IgM assay (LIAISON®).
Table 7: Borrelia specific IgM line blots. Selected samples.
Line blot
Total Positive Equivocal Negative EBV
Recombinant antigen positive Purified flagella antigen negative 1 1 - - -
Recombinant antigen equivocal Purified flagella antigen positive 2 2 - - -
Recombinant antigen negative, Purified flagella antigen positive 43 out of 48 11 4 24 4
Recombinant antigen negative, Purified flagella antigen equivocal 11 out of 16 7 - 4 -BMC Clinical Pathology 2008, 8:4 http://www.biomedcentral.com/1472-6890/8/4
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oratory where most samples will have a low pretest prob-
ability of being from a patient with an acute borrelia
infection. It is important to evaluate diagnostic test on
unselected, population based samples to obtain informa-
tion on how the test discriminate between diseased and
normal groups. If assays are only evaluated on sera from
clearly defined clinical cases, the true performance on
samples submitted from everyday clinical practice where
the diagnosis is unresolved and with a low pretest proba-
bility, will not be known [19]. It is therefore important to
minimise the number of false positive IgM and IgG sam-
ples to avoid uncertainty for the physician and anxiety by
the patient. If truly infected with Borrelia, a new sample
two to four weeks later will in most cases have developed
Borrelia-specific IgG-antibodies [15].
The flagella based assay tested showed more IgM-positive
and IgG-negative results compared to the recombinant
antigen based assay, and using the immunoblot (line
blot) analysis as a independent reference, most of these
reactions appear to be false positive.
Advantage of immunoblots (line blots) has primarily
been evaluated on well defined serum collections. This
introduces a selection bias because samples from unclear
clinical cases are excluded [17]. Such studies will invaria-
bly show much better performance compared to results
from consecutive, unselected samples with a low pretest
probability. This could explain why immunoblots have
shown good performance on selected samples from clini-
cal well defined cases, but are less useful in daily practice
[20].
Based on our comparison the positive outcome from the
purified flagella IgM assay probably has a large proportion
of false positive results using the EcoLine assay as a refer-
ence test. In addition, the recombinant antigen IgG assay
has a better sensitivity compared to the purified flagella
antigen test, but as a result of this also a slightly lower spe-
cificity. There are considerable variation in the B. garinii
OspA surface antigen, and furthermore a study found sub-
stantial genetic diversity in the OspC gene between differ-
ent isolates [21]. Other antigens utilized in diagnostic
assays include the VlsE1 of B. burgdorferi sensu stricto and
B. garinii [22,23].
OspC is an important antigen in the early antibody
response and therefore a major target for Borrelia-specific
IgM-antibodies [24-26]. False positive IgM reactions to
the OspC antigen have been reported from enzyme-
immunoassays [27,28] and immunoblots [29], One study
found a problem of cross reactivity between IgM antibod-
ies from Yersinia and Borrelia [30], but this result has not
been confirmed in other studies.
The value of immunoblotting has been questioned by a
European multicentre study, which showed considerable
variability of the results between centres, and the diagnos-
tic sensitivity and specificity has still not been determined
[31]. One study compared immunoblotting reactivity
against the p17 antigen of B. afzelii and B. garinii on sam-
ples from asymptomatic persons and found large differ-
ences, which could indicate unspecific false positive,
reactivity [32].
However, a positive immunoblot increase the probability
that the primary test was a true positive, but is not a defin-
itive test which can be used as a golden reference standard.
A recent study of Western blotting found that using a mix-
ture of B. burgdorferi sensu stricto and B. afzelii antigens
the diagnosis was improved in up to 70% of sera with bor-
derline results from the enzyme-immunoassays using a
purified flagella antigen (Zeus Scientific, Raritan, United
States) [13].
Conclusion
Our study demonstrate that compared to immunoblots,
an enzyme-immunoassay based on recombinant antigens
(LIAISON®) has fever false positive IgM results and better
IgG sensitivity compared to a flagella-based assay
(IDEIA™). The study showed that for IgM class antibody
testing one kit is not enough because there is large anti-
genic variation in the OspC protein. Thus, tests using
recombinant antigens may have a lower sensitivity. Con-
trary, sharing of antigenic epitopes on flagella among var-
ious bacterial species may result in a lack of specificity and
to a smaller extent lack sensitivity of tests utilizing purified
flagella antigens.
Table 8: Borrelia specific IgG line blots. Selected samples.
Line blot
Total Positive Equivocal Negative EBV
Recombinant antigen positive, Purified flagella antigen negative 12 out of 13 9 3 - -
Recombinant antigen positive, Purified flagella antigen equivocal 1 out of 3 1 - - -
Recombinant antigen equivocal Purified flagella antigen positive 1 1 - - -
Recombinant antigen equivocal Purified flagella antigen negative 3 out of 4 2 - 1 -BMC Clinical Pathology 2008, 8:4 http://www.biomedcentral.com/1472-6890/8/4
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